---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027967"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:51:30.979700+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma Q3 net loss $21.6M; Phase 3 WHIM data on track for Q4; CMO departure, CCO appointed

## Summary
- Net loss of $21.6M for Q3 2022, vs $20.2M in Q3 2021; cash $81.1M as of Sept 30, 2022, sufficient into Q3 2023.
- R&D expenses $14.1M, SG&A $6.0M; PIPE financing gross proceeds $55M in July 2022.
- Phase 3 4WHIM trial top-line data anticipated Q4 2022; NDA submission early H2 2023 if positive.
- Positive Phase 1b data for mavorixafor in chronic neutropenia; trial expanding to Phase 1b/2 in H1 2023.
- Mark Baldry appointed CCO; CMO Diego Cadavid to resign by end of 2022, Dr. Murray Stewart interim CMO.

## SEC filing metadata
- accession: 0001628280-22-027967
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828022027967/0001628280-22-027967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828022027967/xfor-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027967
- JSON: https://secwatch.observer/filing/0001628280-22-027967.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027967.txt

## Key facts
- Earnings Releases
  X4 Pharmaceuticals, Inc reported the third quarter ended September 30, 2022 results: net income $21.6 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: $21.6 million
  - Result: reported results
  source text: X4 reported a net loss of $21.6 million for the third quarter of 2022, as compared to $20.2 million for the comparable period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828022027967/0001628280-22-027967-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.